<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1890" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="1236" end="1241"/>
    <type:OSTime xmi:id="17" sofa="6" begin="1355" end="1361"/>
    <type:PFSTime xmi:id="21" sofa="6" begin="1355" end="1361"/>
    <type:PFSRate xmi:id="25" sofa="6" begin="1388" end="1393"/>
    <type:OSRate xmi:id="29" sofa="6" begin="1398" end="1403"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1435" end="1445"/>
    <type:OSMean xmi:id="37" sofa="6" begin="1479" end="1490"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="This open label, single arm phase II study was designed to evaluate the efficacy &#13;&#10;and safety of the addition of cetuximab to first line chemotherapy with&#13;&#10;carboplatin and weekly docetaxel in patients with advanced non small-cell lung&#13;&#10;cancer (NSCLC). From February 2007 to December 2008 74 patients with NSCLC (stage&#13;&#10;IIIB and IV), ECOG PS =2 and no prior systemic chemotherapy were enrolled and&#13;&#10;treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35&#13;&#10;mg/m(2) on days 1, 8, and 15). Cycles were repeated every 4 weeks for a minimum&#13;&#10;of 4 and a maximum of 6 cycles. Cetuximab (400mg/m(2) on day 1 with subsequent&#13;&#10;doses of 250 mg/m(2) weekly) was administered until progression or intolerable&#13;&#10;toxicity up to a maximum treatment duration of 12 months. The primary endpoint&#13;&#10;was the overall response rate (CR+PR) according to RECIST. Secondary endpoints&#13;&#10;were progression-free survival (PFS), overall survival (OS) and toxicity.&#13;&#10;Patients received a median of 4 cycles of docetaxel-carboplatin-chemotherapy. The&#13;&#10;median number of administrations of cetuximab was 14. Sixty-seven patients were&#13;&#10;evaluable for response. Partial response was seen in 29/67 patients corresponding&#13;&#10;to an overall response rate (ORR) of 43.3% (95%CI, 28.5-53.7). No patient&#13;&#10;experienced complete response. The clinical benefit rate (PR+SD) was 79.1%. The&#13;&#10;1-year rates for PFS and OS were 11.2% and 64.4%, respectively. Median PFS was&#13;&#10;4.8 months (95%CI, 3.70-5.31) and median OS 12.9 months (95%CI 8.26-8). Adverse&#13;&#10;events were mainly grades 1-2. Skin toxicity (76% of pts), dyspnea (36.5%) and&#13;&#10;anemia (31.1%) were most frequent. Results from this phase II study suggest that &#13;&#10;the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel &#13;&#10;results in a considerable clinical efficacy with an acceptable toxicity profile&#13;&#10;for patients with advanced or metastatic NSCLC."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33 37"/>
</xmi:XMI>
